Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint how Genpact recognizes contract revenue or which segment drives its digital transformation growth? With subsidiaries across 25+ countries, Genpact’s disclosures can stretch beyond 250 pages, and the footnotes on long-term service contracts, Data-Tech-AI investments, and client concentration often hide deep inside. If you’re searching for “Genpact SEC filings explained simply,” this page delivers. Stock Titan surfaces the answers in seconds.
Our AI-powered summaries translate every Genpact SEC document—from an 8-K on a new outsourcing deal to the annual report 10-K—into plain language. Whether you search “Genpact insider trading Form 4 transactions” or “understanding Genpact SEC documents with AI,” you’ll find real-time insights, keyword tagging, and cross-linking that make navigation effortless.
Need the latest numbers? The “Genpact quarterly earnings report 10-Q filing” section highlights revenue by vertical, margin movement, and cash-flow trends, while our dashboards compare quarter-over-quarter performance. For governance questions, the proxy statement area breaks down Genpact executive compensation, option awards, and CEO pay ratio. Monitoring management moves? Get instant alerts on “Genpact Form 4 insider transactions real-time” so you never miss a buyback or stock grant.
Every filing type is covered and explained:
- 10-K annual report—strategy shifts, customer concentration, risk factors simplified (“Genpact annual report 10-K simplified”).
- 10-Q quarterly update—data tables annotated, segment commentary summarized (“Genpact earnings report filing analysis”).
- 8-K material events—contract wins or leadership changes distilled (“Genpact 8-K material events explained”).
- Form 4—executive stock moves tracked live (“Genpact executive stock transactions Form 4”).
- DEF 14A proxy—board structure and incentive plans clarified (“Genpact proxy statement executive compensation”).
Stop scrolling through PDFs. Stock Titan delivers real-time filing updates, context-rich charts, and expert analysis tailored to Genpact’s business-process management model—so you can focus on decisions, not document hunting.
Carol Lindstrom, a director of Genpact Limited (ticker G), reported a sale of 2,326 common shares on 08/12/2025 at $43.17 per share. After the disposition she beneficially owned 21,185 shares directly. The filing is limited to a single non-derivative sale and shows no option or derivative activity.
Genpact director Thimaya K. Subaiya received an award of unvested restricted share units (RSUs) under the Genpact Limited 2017 Omnibus Incentive Compensation Plan reported on 08/12/2025. Each RSU converts one-for-one into a common share and the filing shows the reporting person as beneficially owning 2,020 shares following the award. The RSUs fully vest on December 31, 2025 subject to continued service and will be settled in common shares on December 31, 2026. The Form 4 indicates a compensatory grant (price shown as $0) and was filed by a single reporting person.
Genpact Limited submitted a Form 144 notice for the proposed sale of 2,326 common shares, with an aggregate market value of $100,413.42. The shares represent a small fraction of the issuer's outstanding common stock (174,270,076 shares outstanding) and were acquired as restricted stock on 12/31/2019. The broker listed is Morgan Stanley Smith Barney LLC and the securities are designated for sale on the NYSE with an approximate sale date of 08/12/2025. The form indicates no securities sold in the past three months and includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.
Genpact reported continued top-line and profit growth for the quarter ended June 30, 2025. Net revenue rose to $1.254 billion from $1.176 billion a year earlier, while net income increased to $133 million from $122 million, producing diluted EPS of $0.75 versus $0.67. Gross profit and operating income also increased, reflecting higher revenues partially offset by higher SG&A.
The balance sheet expanded: total assets grew to $5.308 billion and shareholders' equity to $2.587 billion. Cash and equivalents were $663 million. The company completed the acquisition of XponentL for total consideration of $159.8 million (including a $77.5 million contingent earn-out recognized at fair value), recording $111.9 million of goodwill and customer/marketing intangibles. Short-term borrowings and the current portion of long-term debt rose (current portion $375.7 million), and the allowance for credit losses on receivables increased to $26.8 million.
FAQ
What is the current stock price of Genpact (G)?
What is the market cap of Genpact (G)?
